Galen E. B. Wright
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Galen E. B. Wright has a total of 256 co-authors. Here are the top co-authors by number of shared publications:
- Britt I. Drogemoller
Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
26 shared publications - Louise Warnich
Stellenbosch University
13 shared publications - Colin James Douglas Ross
Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada
12 shared publications - Michael Reuben Hayden
Department of Medical Genetics, University of British Columbia
9 shared publications - Bruce C. Carleton
Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada
7 shared publications Liezl Koen
Department of Genetics, Stellenbosch University, Stellenbosch, South Africa
4 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 35 (22)
Identifying fundamental properties of neuromuscular disorder genes through genomic feature analysis
Neuromuscular disorders (NMDs) encompass conditions that affect the peripheral nervous system. They are often caused by genetic alterations that impair skeletal muscle function. Molecular diagnosis remains challenging because some causal genes have not yet been identified. We therefore used feature-selection approaches to characterize genomic properties that distinguish NMD genes from other protein-coding genes. Curated genes implicated in NMDs (n = 639; GeneTable of NMDs) were merged with 134 genomic features for autosomal protein-coding genes spanning gene complexity, genetic variation, expression patterns, and other gene traits. Machine-learning-based feature selection using Boruta was combined with statistical analyses to compare NMD genes with other protein-coding genes. We also evaluated NMD genes against high-confidence non-NMD disease genes, examined variation across NMD subgroups, and assessed genes added to the NMD catalogue between 2020 and 2024. Compared with other protein-coding genes, NMD genes showed higher expression in disease-relevant tissues, including skeletal muscle and heart; greater transcript complexity and population genetic constraint, and stronger conservation across several evolutionary measures. Of 33 features that distinguished NMD genes from both high-confidence non-NMD disease genes and other autosomal genes, 28 were expression measures. Feature profiles varied across NMD subgroups, while genes added between 2020 and 2024 showed profiles similar to established NMD genes across all Boruta-confirmed features. This study identified genomic features that distinguish NMD genes from high-confidence disease genes and broader autosomal protein-coding genes. These findings provide insight into the gene architecture, expression, constraint, and evolutionary conservation of NMD genes and may inform candidate-gene prioritization in genetically unresolved NMDs.
- 28 October 2026
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 35 (22)
Open AccessIdentifying fundamental properties of neuromuscular disorder genes through genomic feature analysis
Neuromuscular disorders (NMDs) encompass conditions that affect the peripheral nervous system. They are often caused by genetic alterations that impair skeletal muscle function. Molecular diagnosis remains challenging because some causal genes have not yet been identified. We therefore used feature-selection approaches to characterize genomic properties that distinguish NMD genes from other protein-coding genes. Curated genes implicated in NMDs (n = 639; GeneTable of NMDs) were merged with 134 genomic features for autosomal protein-coding genes spanning gene complexity, genetic variation, expression patterns, and other gene traits. Machine-learning-based feature selection using Boruta was combined with statistical analyses to compare NMD genes with other protein-coding genes. We also evaluated NMD genes against high-confidence non-NMD disease genes, examined variation across NMD subgroups, and assessed genes added to the NMD catalogue between 2020 and 2024. Compared with other protein-coding genes, NMD genes showed higher expression in disease-relevant tissues, including skeletal muscle and heart; greater transcript complexity and population genetic constraint, and stronger conservation across several evolutionary measures. Of 33 features that distinguished NMD genes from both high-confidence non-NMD disease genes and other autosomal genes, 28 were expression measures. Feature profiles varied across NMD subgroups, while genes added between 2020 and 2024 showed profiles similar to established NMD genes across all Boruta-confirmed features. This study identified genomic features that distinguish NMD genes from high-confidence disease genes and broader autosomal protein-coding genes. These findings provide insight into the gene architecture, expression, constraint, and evolutionary conservation of NMD genes and may inform candidate-gene prioritization in genetically unresolved NMDs.
- Open Access
Identifying disease-causing mechanisms and fundamental biology of neuromuscular disorder genes through genomic feature analysis
Introduction: Neuromuscular disorders (NMDs) encompass a broad group of conditions that primarily affect the peripheral nervous system. They are often caused by genetic alterations that impair skeletal muscle function and result in debilitating symptoms. Obtaining an accurate molecular diagnosis remains a challenge, potentially because variants in genes that have yet to be identified as causal. We therefore used advanced computational methods to study the genetic architecture of NMDs and to identify key features that distinguish NMD genes from other genes in the broader genome. Methods: Curated genes implicated in NMDs ( n = 639; GeneTable of NMDs) were obtained and merged with a comprehensive set of genomic features for human autosomal protein-coding genes. Machine-learning-based feature selection and ranking were performed using Boruta, along with complementary analytical approaches. These analyses were used to identify the most important genic features ( n = 134, subcategories: gene complexity, genetic variation, expression patterns, and other general gene traits) for discriminating NMD genes from other genes in the genome Results: NMD genes exhibit enriched expression in disease-relevant tissues, including skeletal muscle and heart. Additionally, compared with other protein-coding genes, these genes exhibit increased transcriptomic complexity (e.g., longer transcripts and more unique isoforms), contain more short tandem repeats, and show greater variation in conservation across model organisms. Conclusions: This study identified several key genomic features that may distinguish NMD genes from the rest of the genome. This may enhance the identification of novel causal genes and could ultimately facilitate earlier diagnosis and medical management for affected individuals.
Open AccessIdentifying disease-causing mechanisms and fundamental biology of neuromuscular disorder genes through genomic feature analysis
Introduction: Neuromuscular disorders (NMDs) encompass a broad group of conditions that primarily affect the peripheral nervous system. They are often caused by genetic alterations that impair skeletal muscle function and result in debilitating symptoms. Obtaining an accurate molecular diagnosis remains a challenge, potentially because variants in genes that have yet to be identified as causal. We therefore used advanced computational methods to study the genetic architecture of NMDs and to identify key features that distinguish NMD genes from other genes in the broader genome. Methods: Curated genes implicated in NMDs ( n = 639; GeneTable of NMDs) were obtained and merged with a comprehensive set of genomic features for human autosomal protein-coding genes. Machine-learning-based feature selection and ranking were performed using Boruta, along with complementary analytical approaches. These analyses were used to identify the most important genic features ( n = 134, subcategories: gene complexity, genetic variation, expression patterns, and other general gene traits) for discriminating NMD genes from other genes in the genome Results: NMD genes exhibit enriched expression in disease-relevant tissues, including skeletal muscle and heart. Additionally, compared with other protein-coding genes, these genes exhibit increased transcriptomic complexity (e.g., longer transcripts and more unique isoforms), contain more short tandem repeats, and show greater variation in conservation across model organisms. Conclusions: This study identified several key genomic features that may distinguish NMD genes from the rest of the genome. This may enhance the identification of novel causal genes and could ultimately facilitate earlier diagnosis and medical management for affected individuals.
- Open Access
A computational model for quantifying instability of tandem repeats across the genome
Tandem repeats (TRs) exhibit high levels of somatic mosaicism, which is increasingly recognized as an important modifier of repeat expansion disorders. Long-read sequencing can capture full-length repeat alleles, yet robust frameworks for quantifying instability across TRs genome-wide are still needed. Here, we introduce a general-purpose model for quantifying TR instability in a given long-read sequencing dataset, without explicitly distinguishing biological mosaicism from technical noise, and which is broadly applicable to both simple and structurally complex loci. This model accurately characterizes allelic instability at each TR locus by representing the distribution of read-to-consensus deviations for each allele. Using HiFi sequencing data from 256 HPRC cell line samples, we fitted models for 617,007 TR loci, including known pathogenic repeats. We observe that instability levels are generally low, but vary substantially across individual TRs, and are driven more strongly by repeat composition than overall repeat length. Furthermore, we applied our method to targeted PureTarget long-read data from samples with known repeat expansions and identified significant mosaicism in the majority of expanded alleles. Our model offers a practical way to quantify instability of tandem repeats across the genome and to detect unusually unstable repeat alleles.
Open AccessA computational model for quantifying instability of tandem repeats across the genome
Tandem repeats (TRs) exhibit high levels of somatic mosaicism, which is increasingly recognized as an important modifier of repeat expansion disorders. Long-read sequencing can capture full-length repeat alleles, yet robust frameworks for quantifying instability across TRs genome-wide are still needed. Here, we introduce a general-purpose model for quantifying TR instability in a given long-read sequencing dataset, without explicitly distinguishing biological mosaicism from technical noise, and which is broadly applicable to both simple and structurally complex loci. This model accurately characterizes allelic instability at each TR locus by representing the distribution of read-to-consensus deviations for each allele. Using HiFi sequencing data from 256 HPRC cell line samples, we fitted models for 617,007 TR loci, including known pathogenic repeats. We observe that instability levels are generally low, but vary substantially across individual TRs, and are driven more strongly by repeat composition than overall repeat length. Furthermore, we applied our method to targeted PureTarget long-read data from samples with known repeat expansions and identified significant mosaicism in the majority of expanded alleles. Our model offers a practical way to quantify instability of tandem repeats across the genome and to detect unusually unstable repeat alleles.
- Open Access
- 20 November 2025
- Published by Elsevier in Human Genetics and Genomics Advances
- Vol. 7 (1) , 100547
Unbiased human genomic characterization of polyglutamine disorder genes to guide biological understanding and therapeutic strategies
- 20 November 2025
- Published by Elsevier in Human Genetics and Genomics Advances
- Vol. 7 (1) , 100547
Open AccessUnbiased human genomic characterization of polyglutamine disorder genes to guide biological understanding and therapeutic strategies
- Open Access
Unbiased human genomic characterization of polyglutamine disorder genes to guide biological understanding and therapeutic strategies
Background: Polyglutamine (polyQ) disorders, such as Huntington disease (HD) and several spinocerebellar ataxias, are severe neurological disorders caused by glutamine codon repeat expansions. These conditions lack effective treatments, with therapeutic research focused on pathogenic gene knockdown. Objectives: We aimed to profile these genes using diverse human genomic data to inform therapeutic strategies by identifying new biology and assessing the potential on-target effects of knocking down these genes. Methods: We conducted an unbiased phenome-wide study to identify human traits and diseases linked to polyQ disorder genes (Open Targets L2G>0.5). Network analyses explored shared trait associations and overlapping biological processes among these genes. Lastly, we assessed the theoretical druggability of polyQ disorder genes using recently identified features predictive of clinical trial success and compared them to repeat expansion (HD) modifier genes. Results: We identified 215 human phenotype/polyQ disorder gene associations from 3,095 studies, indicating potential adverse effects from gene knockdown. Shared trait associations among genes suggested overlapping biological processes despite distinct functions. Drug target profile analysis revealed unfavorable risk profiles for polyQ disorder genes, particularly ATN1 , ATXN1 , ATXN7 , and HTT , due to genomic features such as constraint, molecular interactions, and tissue specificity. PolyQ disorder genes also showed significantly more safety-related risks than HD genetic modifier genes ( P =7.03×10 -3 ). Conclusion: Our analyses emphasize the pleiotropic nature of polyQ disorder genes, highlighting their potential risks as drug targets. These findings reinforce the importance of exploring alternative therapeutic strategies, such as targeting genetic modifier genes, as well as allele-selective approaches, to mitigate these challenges.
Open AccessUnbiased human genomic characterization of polyglutamine disorder genes to guide biological understanding and therapeutic strategies
Background: Polyglutamine (polyQ) disorders, such as Huntington disease (HD) and several spinocerebellar ataxias, are severe neurological disorders caused by glutamine codon repeat expansions. These conditions lack effective treatments, with therapeutic research focused on pathogenic gene knockdown. Objectives: We aimed to profile these genes using diverse human genomic data to inform therapeutic strategies by identifying new biology and assessing the potential on-target effects of knocking down these genes. Methods: We conducted an unbiased phenome-wide study to identify human traits and diseases linked to polyQ disorder genes (Open Targets L2G>0.5). Network analyses explored shared trait associations and overlapping biological processes among these genes. Lastly, we assessed the theoretical druggability of polyQ disorder genes using recently identified features predictive of clinical trial success and compared them to repeat expansion (HD) modifier genes. Results: We identified 215 human phenotype/polyQ disorder gene associations from 3,095 studies, indicating potential adverse effects from gene knockdown. Shared trait associations among genes suggested overlapping biological processes despite distinct functions. Drug target profile analysis revealed unfavorable risk profiles for polyQ disorder genes, particularly ATN1 , ATXN1 , ATXN7 , and HTT , due to genomic features such as constraint, molecular interactions, and tissue specificity. PolyQ disorder genes also showed significantly more safety-related risks than HD genetic modifier genes ( P =7.03×10 -3 ). Conclusion: Our analyses emphasize the pleiotropic nature of polyQ disorder genes, highlighting their potential risks as drug targets. These findings reinforce the importance of exploring alternative therapeutic strategies, such as targeting genetic modifier genes, as well as allele-selective approaches, to mitigate these challenges.
- Open Access
- 24 December 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (1) , fcae418
Genomic characterization of Huntington’s disease genetic modifiers informs drug target tractability
Huntington’s disease is caused by a CAG repeat in the HTT gene. Repeat length correlates inversely with the age of onset but only explains part of the observed clinical variability. Genome-wide association studies highlight DNA repair genes in modifying disease onset, but further research is required to identify causal genes and evaluate their tractability as drug targets. To address these gaps and learn important preclinical information, we analysed genome-wide association study data from a large Huntington’s disease age-of-onset study (n = 9064), prioritizing robust candidate Huntington’s disease modifier genes using bioinformatic approaches and analysing related information for these genes from large-scale human genetic repositories. We supplemented this information with other Huntington’s disease–related screens, including exome studies of Huntington’s disease onset and high-throughput assessments of mHTT toxicity. To confirm whether Huntington’s disease modifiers are shared across repeat expansion disorders, we also analysed age-of-onset genome-wide association study data from X-linked dystonia-parkinsonism caused by a (CCCTCT)n expansion. We also studied modifier-related associations with rare diseases to inform potential off-target therapeutic effects and conducted comprehensive phenome-wide studies to identify other traits linked to these genes. Finally, we evaluated the aggregated human genetic evidence and theoretical druggability of the prioritized Huntington’s disease modifier genes, including characteristics recently associated with clinical trial stoppage due to safety concerns (i.e. human genetic constraint, number of interacting partners and RNA tissue expression specificity). In total, we annotated and assessed nine robust candidate Huntington’s disease modifier genes. Notably, we detected a high correlation (R2 = 0.78) in top age-of-onset genome-wide association study hits across repeat expansion disorders, emphasizing cross-disorder relevance. Clinical genetic repositories analysis showed DNA repair genes, such as MLH1, PMS2 and MSH3, are associated with cancer phenotypes, suggesting potential limitations as drug targets. LIG1 and RRM2B were both associated with neurofibrillary tangles, which may provide a link to a potential role in mHTT aggregates, while MSH3 was associated with several cortical morphology-related traits relevant to Huntington’s disease. Finally, human genetic evidence and theoretical druggability analyses prioritized and ranked modifier genes, with PMS1 exhibiting the most favourable profile. Notably, HTT itself ranked poorly as a theoretical drug target, emphasizing the importance of exploring modifier-based alternative targets. In conclusion, our study highlights the importance of human genomic information to prioritize Huntington’s disease modifier genes as drug targets, providing a basis for future therapeutic development in Huntington’s disease and other repeat expansion disorders.
- 24 December 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (1) , fcae418
Open AccessGenomic characterization of Huntington’s disease genetic modifiers informs drug target tractability
Huntington’s disease is caused by a CAG repeat in the HTT gene. Repeat length correlates inversely with the age of onset but only explains part of the observed clinical variability. Genome-wide association studies highlight DNA repair genes in modifying disease onset, but further research is required to identify causal genes and evaluate their tractability as drug targets. To address these gaps and learn important preclinical information, we analysed genome-wide association study data from a large Huntington’s disease age-of-onset study (n = 9064), prioritizing robust candidate Huntington’s disease modifier genes using bioinformatic approaches and analysing related information for these genes from large-scale human genetic repositories. We supplemented this information with other Huntington’s disease–related screens, including exome studies of Huntington’s disease onset and high-throughput assessments of mHTT toxicity. To confirm whether Huntington’s disease modifiers are shared across repeat expansion disorders, we also analysed age-of-onset genome-wide association study data from X-linked dystonia-parkinsonism caused by a (CCCTCT)n expansion. We also studied modifier-related associations with rare diseases to inform potential off-target therapeutic effects and conducted comprehensive phenome-wide studies to identify other traits linked to these genes. Finally, we evaluated the aggregated human genetic evidence and theoretical druggability of the prioritized Huntington’s disease modifier genes, including characteristics recently associated with clinical trial stoppage due to safety concerns (i.e. human genetic constraint, number of interacting partners and RNA tissue expression specificity). In total, we annotated and assessed nine robust candidate Huntington’s disease modifier genes. Notably, we detected a high correlation (R2 = 0.78) in top age-of-onset genome-wide association study hits across repeat expansion disorders, emphasizing cross-disorder relevance. Clinical genetic repositories analysis showed DNA repair genes, such as MLH1, PMS2 and MSH3, are associated with cancer phenotypes, suggesting potential limitations as drug targets. LIG1 and RRM2B were both associated with neurofibrillary tangles, which may provide a link to a potential role in mHTT aggregates, while MSH3 was associated with several cortical morphology-related traits relevant to Huntington’s disease. Finally, human genetic evidence and theoretical druggability analyses prioritized and ranked modifier genes, with PMS1 exhibiting the most favourable profile. Notably, HTT itself ranked poorly as a theoretical drug target, emphasizing the importance of exploring modifier-based alternative targets. In conclusion, our study highlights the importance of human genomic information to prioritize Huntington’s disease modifier genes as drug targets, providing a basis for future therapeutic development in Huntington’s disease and other repeat expansion disorders.
- Open Access
- 20 December 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (3) , 576-594
Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub‐Saharan African Populations
Genetic variation in CYP2B6 and CYP2A6 is known to impact interindividual response to antiretrovirals, nicotine, and bupropion, among other drugs. However, the full catalogue of clinically relevant pharmacogenetic variants in these genes is yet to be established, especially across African populations. This study therefore aimed to characterize the star allele (haplotype) distribution in CYP2B6 and CYP2A6 across diverse and understudied sub‐Saharan African (SSA) populations. We called star alleles from 961 high‐depth full genomes using StellarPGx, Aldy, and PyPGx. In addition, we performed CYP2B6 and CYP2A6 star allele frequency comparisons between SSA and other global biogeographical groups represented in the new 1000 Genomes Project high‐coverage dataset (n = 2,000). This study presents frequency information for star alleles in CYP2B6 (e.g., *6 and *18; frequency of 21–47% and 2–19%, respectively) and CYP2A6 (e.g., *4, *9, and *17; frequency of 0–6%, 3–10%, and 6–20%, respectively), and predicted phenotypes (for CYP2B6), across various African populations. In addition, 50 potentially novel African‐ancestry star alleles were computationally predicted by StellarPGx in CYP2B6 and CYP2A6 combined. For each of these genes, over 4% of the study participants had predicted novel star alleles. Three novel star alleles in CYP2A6 (*54, *55, and *56) and CYP2B6 apiece, and several suballeles were further validated via targeted Single‐Molecule Real‐Time resequencing. Our findings are important for informing the design of comprehensive pharmacogenetic testing platforms, and are highly relevant for personalized medicine strategies, especially relating to antiretroviral medication and smoking cessation treatment in Africa and the African diaspora. More broadly, this study highlights the importance of sampling diverse African ethnolinguistic groups for accurate characterization of the pharmacogene variation landscape across the continent.
- 20 December 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (3) , 576-594
Open AccessCharacterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub‐Saharan African Populations
Genetic variation in CYP2B6 and CYP2A6 is known to impact interindividual response to antiretrovirals, nicotine, and bupropion, among other drugs. However, the full catalogue of clinically relevant pharmacogenetic variants in these genes is yet to be established, especially across African populations. This study therefore aimed to characterize the star allele (haplotype) distribution in CYP2B6 and CYP2A6 across diverse and understudied sub‐Saharan African (SSA) populations. We called star alleles from 961 high‐depth full genomes using StellarPGx, Aldy, and PyPGx. In addition, we performed CYP2B6 and CYP2A6 star allele frequency comparisons between SSA and other global biogeographical groups represented in the new 1000 Genomes Project high‐coverage dataset (n = 2,000). This study presents frequency information for star alleles in CYP2B6 (e.g., *6 and *18; frequency of 21–47% and 2–19%, respectively) and CYP2A6 (e.g., *4, *9, and *17; frequency of 0–6%, 3–10%, and 6–20%, respectively), and predicted phenotypes (for CYP2B6), across various African populations. In addition, 50 potentially novel African‐ancestry star alleles were computationally predicted by StellarPGx in CYP2B6 and CYP2A6 combined. For each of these genes, over 4% of the study participants had predicted novel star alleles. Three novel star alleles in CYP2A6 (*54, *55, and *56) and CYP2B6 apiece, and several suballeles were further validated via targeted Single‐Molecule Real‐Time resequencing. Our findings are important for informing the design of comprehensive pharmacogenetic testing platforms, and are highly relevant for personalized medicine strategies, especially relating to antiretroviral medication and smoking cessation treatment in Africa and the African diaspora. More broadly, this study highlights the importance of sampling diverse African ethnolinguistic groups for accurate characterization of the pharmacogene variation landscape across the continent.
- Open Access
- 21 October 2022
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 113 (3) , 643-659
Characterization of CYP2D6 Pharmacogenetic Variation in Sub‐Saharan African Populations
Cytochrome P450 2D6 (CYP2D6) is a key enzyme in drug response owing to its involvement in the metabolism of ~ 25% of clinically prescribed medications. The encoding CYP2D6 gene is highly polymorphic, and many pharmacogenetics studies have been performed worldwide to investigate the distribution of CYP2D6 star alleles (haplotypes); however, African populations have been relatively understudied to date. In this study, the distributions of CYP2D6 star alleles and predicted drug metabolizer phenotypes—derived from activity scores—were examined across multiple sub‐Saharan African populations based on bioinformatics analysis of 961 high‐depth whole genome sequences. This was followed by characterization of novel star alleles and suballeles in a subset of the participants via targeted high‐fidelity Single‐Molecule Real‐Time resequencing (Pacific Biosciences). This study revealed varying frequencies of known CYP2D6 alleles and predicted phenotypes across different African ethnolinguistic groups. Twenty‐seven novel CYP2D6 star alleles were predicted computationally and two of them were further validated. This study highlights the importance of studying variation in key pharmacogenes such as CYP2D6 in the African context to better understand population‐specific allele frequencies. This will aid in the development of better genotyping panels and star allele detection approaches with a view toward supporting effective implementation of precision medicine strategies in Africa and across the African diaspora.
- 21 October 2022
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 113 (3) , 643-659
Open AccessCharacterization of CYP2D6 Pharmacogenetic Variation in Sub‐Saharan African Populations
Cytochrome P450 2D6 (CYP2D6) is a key enzyme in drug response owing to its involvement in the metabolism of ~ 25% of clinically prescribed medications. The encoding CYP2D6 gene is highly polymorphic, and many pharmacogenetics studies have been performed worldwide to investigate the distribution of CYP2D6 star alleles (haplotypes); however, African populations have been relatively understudied to date. In this study, the distributions of CYP2D6 star alleles and predicted drug metabolizer phenotypes—derived from activity scores—were examined across multiple sub‐Saharan African populations based on bioinformatics analysis of 961 high‐depth whole genome sequences. This was followed by characterization of novel star alleles and suballeles in a subset of the participants via targeted high‐fidelity Single‐Molecule Real‐Time resequencing (Pacific Biosciences). This study revealed varying frequencies of known CYP2D6 alleles and predicted phenotypes across different African ethnolinguistic groups. Twenty‐seven novel CYP2D6 star alleles were predicted computationally and two of them were further validated. This study highlights the importance of studying variation in key pharmacogenes such as CYP2D6 in the African context to better understand population‐specific allele frequencies. This will aid in the development of better genotyping panels and star allele detection approaches with a view toward supporting effective implementation of precision medicine strategies in Africa and across the African diaspora.
- Open Access
- 9 July 2022
- Published by Springer Nature in Cell Death Discovery
- Vol. 8 (1) , 1-4
Common huntingtin-related genetic variation is associated with neurobiological and aging traits in humans
- 9 July 2022
- Published by Springer Nature in Cell Death Discovery
- Vol. 8 (1) , 1-4
Open AccessCommon huntingtin-related genetic variation is associated with neurobiological and aging traits in humans
- Open Access
- 25 December 2021
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 111 (4) , 919-930
A Systematic Review and Analysis of the Use of Polygenic Scores in Pharmacogenomics
Polygenic scores (PGSs) have emerged as promising tools for complex trait risk prediction. The application of these scores to pharmacogenomics provides new opportunities to improve the prediction of treatment outcomes. To gain insight into this area of research, we conducted a systematic review and accompanying analysis. This review uncovered 51 papers examining the use of PGSs for drug‐related outcomes, with the majority of these papers focusing on the treatment of psychiatric disorders (n = 30). Due to difficulties in collecting large cohorts of uniformly treated patients, the majority of pharmacogenomic PGSs were derived from large‐scale genome‐wide association studies of disease phenotypes that were related to the pharmacogenomic phenotypes under investigation (e.g., schizophrenia‐derived PGSs for antipsychotic response prediction). Examination of the research participants included in these studies revealed that the majority of cohort participants were of European descent (78.4%). These biases were also reflected in research affiliations, which were heavily weighted towards institutions located in Europe and North America, with no first or last authors originating from institutions in Africa or South Asia. There was also substantial variability in the methods used to develop PGSs, with between 3 and 6.6 million variants included in the PGSs. Finally, we observed significant inconsistencies in the reporting of PGS analyses and results, particularly in terms of risk model development and application, coupled with a lack of data transparency and availability, with only three pharmacogenomics PGSs deposited on the Polygenic Score Catalog. These findings highlight current gaps and key areas for future pharmacogenomic PGS research.
- 25 December 2021
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 111 (4) , 919-930
Open AccessA Systematic Review and Analysis of the Use of Polygenic Scores in Pharmacogenomics
Polygenic scores (PGSs) have emerged as promising tools for complex trait risk prediction. The application of these scores to pharmacogenomics provides new opportunities to improve the prediction of treatment outcomes. To gain insight into this area of research, we conducted a systematic review and accompanying analysis. This review uncovered 51 papers examining the use of PGSs for drug‐related outcomes, with the majority of these papers focusing on the treatment of psychiatric disorders (n = 30). Due to difficulties in collecting large cohorts of uniformly treated patients, the majority of pharmacogenomic PGSs were derived from large‐scale genome‐wide association studies of disease phenotypes that were related to the pharmacogenomic phenotypes under investigation (e.g., schizophrenia‐derived PGSs for antipsychotic response prediction). Examination of the research participants included in these studies revealed that the majority of cohort participants were of European descent (78.4%). These biases were also reflected in research affiliations, which were heavily weighted towards institutions located in Europe and North America, with no first or last authors originating from institutions in Africa or South Asia. There was also substantial variability in the methods used to develop PGSs, with between 3 and 6.6 million variants included in the PGSs. Finally, we observed significant inconsistencies in the reporting of PGS analyses and results, particularly in terms of risk model development and application, coupled with a lack of data transparency and availability, with only three pharmacogenomics PGSs deposited on the Polygenic Score Catalog. These findings highlight current gaps and key areas for future pharmacogenomic PGS research.